Maximizing Outcomes in Relapsed/Refractory Multiple Myeloma: Tailoring Bispecific Antibody Approaches : Episode 2
MonumenTAL: Key Efficacy Outcomes
Dr Nadeem to summarize the clinical evidence supporting talquetamab use in relapsed/refractory multiple myeloma, including key efficacy outcomes from the monumenTAL trials.
Video content above is prompted by the following:
- What characteristics make this patient particularly suitable for treatment with a bispecific antibody?
- Can you summarize the clinical evidence supporting talquetamab use in relapsed/refractory multiple myeloma (R/R MM)?
- Could you highlight the primary efficacy outcomes from the monumenTAL trials?
Recent Videos
Related Content
